This book explores the complex interplay between neuroinflammation and autophagy, offering a comprehensive understanding of how these processes drive the development and progression of neurodegenerative diseases. It establishes how chronic inflammation not only disrupts autophagy but also creates feedback loops that exacerbate cellular dysfunction and accelerate neurodegeneration.

The book's core focus is on presenting biological processes at the cellular level, such as neuronal function, glial activation, and protein aggregation in multiple metabolic brain diseases. It discusses key pathways such as mTOR, AMPK, and inflammasomes that directly affect neuronal function. It contains dedicated chapters on Alzheimer's, Parkinson's, ALS, Huntington's, and Multiple Sclerosis, offering disease-specific insights and tailored discussions for each condition. The book complements these mechanistic insights with therapeutic strategies, lifestyle interventions, and emerging trends in biomarkers and personalized medicine. It highlights emerging treatments, repurposed anti-inflammatory drugs, and the neuroprotective property of diet and microbiome. Thus, this book establishes a multidisciplinary perspective combining insights from neuroscience, molecular biology, immunology, and pathology to provide a well-rounded understanding of neurodegenerative mechanisms and therapies.

The emphasis on dual-pathway modulation and the holistic perspective in the book makes it an essential resource for researchers, clinicians, and healthcare professionals in neurology and neurobiology who seek a comprehensive understanding of neurodegenerative disease mechanisms. Graduate and advanced undergraduate students in neuroscience will also benefit from the detailed exploration of cellular pathways and therapeutic strategies.

Presents insights into the cellular pathways of neurodegeneration including mTOR, AMPK, Beclin-1, and inflammasomes Discusses the contributions of mitochondrial dysfunction and ER stress to oxidative stress and autophagy impairment Covers advanced pharmacological interventions targeting both autophagy and neuroinflammation

Autorentext

Dr. Pukar Khanal, a research fellow at the School of Medicine, Emory University, GA, United States completed his bachelor’s degree in Pharmaceutical Science and master’s degree in Pharmacology from KLE University, Belagavi, India, and obtained his Ph.D. from KLE Academy of Higher Education and Research, India. He has been involved in research on neurological, cancer, and endocrine disorders, focusing on identifying potential drug-like small molecules using both computational and experimental approaches, including drug repurposing. He is also interested in utilizing Danio rerio as an alternative animal model and has proposed its use for studying olanzapine-induced weight gain. His current research interests include understanding deregulated metabolic processes in neurodegeneration, particularly glucose and lipid homeostasis in the brain. Dr. Khanal has published research in journals of international repute, serves on the editorial boards of journals such as CNS & Neurological Disorders - Drug Targets, Frontiers in Pharmacology, and Pharmacological Research-Reports, and has been honored with Gold Medals twice by the KLE Academy of Higher Education and Research for his academic achievements.

Dr. B. M. Patil, a life member of the Indian Pharmaceutical Association, Indian Pharmacological Society (IPS), and the Association of Pharmacy Teachers of India (APTI), is currently serving as Senior Professor & Director at Pravara Rural College of Pharmacy, Loni, Maharashtra. With over 35 years of experience in academia and research, Dr. Patil has held various key positions, including Professor, Principal, and Dean at KLE College of Pharmacy, Belagavi and Hubballi, India. Dr. Patil has made significant contributions to pharmacological research, particularly in rodent models of insulin resistance, metabolic syndrome, diabetes, obesity, endothelial dysfunction, and Alzheimer's disease. His research also emphasizes network pharmacology and drug development. He has been instrumental in guiding 8 Ph.D. candidates and 92 M. Pharm dissertations. His expertise has led to securing major research grants, including AICTE-funded projects and collaborations with the Himalaya Drug Company. His research projects have been funded by organizations such as AICTE and industry partners, focusing on areas like marker-assisted selection for metabolic and neurodegenerative diseases. Dr. Patil's contributions to the field have been recognized through several prestigious awards, including the Best Teacher Award, the Prof. M. L. Khorana Memorial Award, and a Certificate of Outstanding Contribution in Reviewing from Elsevier. In addition to his research, Dr. Patil has actively served on numerous academic committees, including Ph.D. selection and registration committees at institutions such as Sanjay Ghodawat University and Rajiv Gandhi University of Health Sciences. He has also been a board member for pharmacy education at several universities.

Dr. Rupesh V. Chikhale is an affiliated scientist with the Cambridge Crystallographic Data Centre at the University of Cambridge, UK with postdoctoral training from the School of Pharmacy, Faculty of Life Sciences, University College London, Dr. Chikhale specializes in structural biology and drug discovery. His research utilizes crystallographic and computational methods to investigate molecular interactions critical to therapeutic development, aiming to identify potential drug candidates in areas where structural data is often limited or challenging to acquire. He has contributed extensively to the field through publications in prominent international journals and collaborative projects in drug discovery. Dr. Chikhale brings expertise in advanced structural biology techniques and data analysis, helping to bridge chemistry and biology innovatively.

Klappentext

Part I: Neuroinflammation and Autophagy in Neurodegenerative Disease .- Chapter 1: Neuroinflammation and Its Impact on Autophagy in Neurodegeneration .- Chapter 2: Mechanisms of Autophagy and Its Dysregulation in Neurodegenerative Diseases .- Chapter 3: Glial Cells, Cytokines, and Inflammasomes in Neurodegeneration .- Chapter 4: Mitochondrial Dysfunction, Endoplasmic Reticulum Stress, and Their Role in Neurodegeneration .- Chapter 5: Protein Aggregation, Oxidative Stress, and Autophagic Dysfunction in Neurodegenerative Diseases .- Chapter 6: Blood-Brain Barrier Dysfunction in Neuroinflammation and Autophagy .- Chapter 7: Epigenetic Regulations of Neuroinflammatory and Autophagic Pathways Part II: Neurodegenerative Diseases and Mechanistic Insights .- Chapter 8: Autophagy and Neuroinflammatory Pathways in Alzheimer’s Disease .- Chapter 9: Inflammation and Autophagic Dysfunction in Parkinson’s disease .- Chapter 10:Glial Activation and Autophagic Imbalance in Amyotrophic Lateral Sclerosis .- Chapter 11:Protein Aggregation and Neuroinflammation in Huntington’s Disease .- Chapter 12:Inflammatory Demyelination and Autophagic Dysfunction in Multiple Sclerosis .- Chapter 13:Disrupted Cellular Clearance and Inflammatory Loops in Frontotemporal Dementia Part III: Therapeutic Strategies and Emerging Research .- Chapter 14:Neuroinflammation and Autophagy in Neurodegenerative Therapy .- Chapter 15:Advanced Delivery Systems and Gene Editing in Neurotherapeutics .- Chapter 16:Lifestyle, Diet, and the Gut-Brain Axis in Neuroprotection .- Chapter 17:Biomarkers to Personalized Therapies in Neurodegenerative Medicine.

Inhalt

Part I: Neuroinflammation and Autophagy in Neurodegenerative Disease
.- Chapter 1: Neuroinflammation and Its Impact on Autophagy in Neurodegeneration
.- Chapter 2: Mechanisms of Autophagy and Its Dysregulation in Neurodegenerative Diseases
.- Chapter 3: Glial Cells, Cytoki…